{"title":"Deucravacitinib治疗中度至重度斑块性银屑病","authors":"Steve Chaplin","doi":"10.1002/psb.2089","DOIUrl":null,"url":null,"abstract":"Deucravacitinib (Sotyktu) is a new small‐molecule TYK2 inhibitor for the treatment of adults with moderate to severe plaque psoriasis. This article outlines its mode of action, efficacy and place in therapy.","PeriodicalId":20432,"journal":{"name":"Prescriber","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Deucravacitinib for moderate to severe plaque psoriasis\",\"authors\":\"Steve Chaplin\",\"doi\":\"10.1002/psb.2089\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Deucravacitinib (Sotyktu) is a new small‐molecule TYK2 inhibitor for the treatment of adults with moderate to severe plaque psoriasis. This article outlines its mode of action, efficacy and place in therapy.\",\"PeriodicalId\":20432,\"journal\":{\"name\":\"Prescriber\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/psb.2089\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/psb.2089","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Deucravacitinib for moderate to severe plaque psoriasis
Deucravacitinib (Sotyktu) is a new small‐molecule TYK2 inhibitor for the treatment of adults with moderate to severe plaque psoriasis. This article outlines its mode of action, efficacy and place in therapy.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
